<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93023">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893905</url>
  </required_header>
  <id_info>
    <org_study_id>TM-CS+SG /301</org_study_id>
    <secondary_id>2013-000444-26</secondary_id>
    <nct_id>NCT01893905</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a New Formulation of Chondroitin Sulfate and Glucosamine Sulfate to Treat Knee Osteoarthritis</brief_title>
  <official_title>Phase III Clinical Trial to Evaluate the Efficacy and Safety of Chondroitin Sulfate and Glucosamine Sulfate in Combination Versus Placebo in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tedec-Meiji Farma, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tedec-Meiji Farma, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to assess the efficacy of a new formulation containing chondroitin
      sulfate and glucosamine sulfate (CS+GS) compared with placebo in patients with primary
      osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether a new combination of chondroitin sulfate
      and glucosamine sulfate administered once a day is superior to placebo in the treatment of
      patients with moderate to severe knee osteoarthritis. Eligible patients will be ranzomized
      1:1 and the treatments will be administered for 24 weeks. Clinical efficacy at the end of
      treatment will be evaluated. Safety will be evaluated through adverse events recoding during
      the study period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of pain using VAS</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OMERACT-OARSI responder criteria</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Index (pain, stiffness and function)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator global assessment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of rescue medication</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events recording</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">193</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>CS+SG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chondroitin sulfate 1200mg+ glucosamine sulfate 1500mg orally administered once a day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of chondroitin sulfate + glucosamine sulfate orally administered once a day for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS+SG</intervention_name>
    <description>Chondroitin sulfate+glucosamine sulfate orallly administered once a day for 24 weeks.</description>
    <arm_group_label>CS+SG</arm_group_label>
    <other_name>Chondroitin sulfate+glucosamine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of chondroitin sulfate+glucosamine sulfate orallly administered once a day for 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo chondroitin sulfate+glucosamine sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient &gt;= 45 years .

          -  Primary OA of the knee according to ACR criteria.

          -  OA radiological grade II-III according to Kellgren and Lawrence.

          -  Patients with moderate-severe pain.

        Exclusion Criteria:

          -  Patients with clinical significant trauma or surgery in the target knee.

          -  Concurrent arthritic disease (antecedents and/or current signs) that could confound
             or interfere with the evaluation of pain efficacy such as chondrocalcinosis, Paget's
             disease of the ipsilateral limb to the target knee, rheumatoid arthritis, aseptic
             osteonecrosis, gout, septic arthritis, ochronosis, acromegaly, haemochromatosis,
             Wilson's disease, osteochondromatosis, seronegative spondyloarthropathy, mixed
             connective tissue disease, collagen vascular disease, psoriasis, inflammatory bowel
             disease or fibromyalgia.

          -  Pain in other parts of the body greater than the knee pain that could interfere with
             the evaluation.

          -  Subjects with any active acute or chronic infections requiring antimicrobial therapy,
             or serious viral (e.g., hepatitis, herpes zoster, HIV positivity) or fungal
             infections.

          -  Clinical diagnosis established of uncontrolled diabetes mellitus.

          -  Patients with asthma.

          -  History of hypersensitivity to the active drugs or any excipients of the
             formulations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FJ Blanco, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Universitario La Coru√±a</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Several study sites</name>
      <address>
        <city>(multicentric Study)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 19, 2015</lastchanged_date>
  <firstreceived_date>July 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
